Log In
Print
BCIQ
Print
Print this Print this
 

Bystolic, nebivolol

  Manage Alerts
Collapse Summary General Information
Company Actavis plc
DescriptionAdrenergic receptor beta 1 (ADRB1) antagonist
Molecular Target Adrenergic receptor beta 1 (ADRB1)
Mechanism of ActionAdrenergic receptor beta 1 (ADRB1) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat hypertension; Treat mild to moderate stage I and II hypertension
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$357.0M

$357.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today